Sanofi hits the brakes on a top pivotal program following 'new adverse events'
According to a trio of hemophilia patient groups, Sanofi has hit the brakes on a slate of late-stage studies for fitusiran, one of their Phase III programs held up by CEO Paul Hudson as a top prospect needed to help the turnaround he’s been pushing hard at the pharma giant. The drug has been linked to new cases of thrombosis, which triggered an earlier halt 3 years ago.
A statement from the World Federation of Hemophilia, the European Haemophilia Consortium and the National Hemophilia Foundation notes that they had “confirmed a decision by Sanofi Genzyme to initiate a voluntary sponsor-led global dosing hold on its full clinical development program for fitusiran due to the identification of new adverse events.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,000+ biopharma pros reading Endpoints daily — and it's free.